99.41
-0.76
(-0.76%)
Real-time:
10:18AM EDT
NYSE
real-time data -
Disclaimer
Currency in USD
| Range | 99.04 - 99.76 |
| 52 week | 71.56 - 102.72 |
| Open | 99.57 |
| Vol / Avg. | 50,379.00/1.05M |
| Mkt cap | 19.31B |
| P/E | 17.69 |
| Div/yield | 0.50/1.99 |
| EPS | 5.62 |
| Shares | 194.25M |
| Beta | 0.68 |
| Inst. own | 84% |
Events
Aug 2, 2013
Q3 2013 BD Earnings Release
May 30, 2013
BD at 38th Annual dbAccess Health Care Conference
- 10:40AM EDT -
May 2, 2013
Q2 2013 BD Earnings Conference Call -
May 1, 2013
Q2 2013 BD Earnings Release
Mar 28, 2013
BD Corporate Conference Call to Discuss New Product Line -
Mar 13, 2013
BD at Barclays Healthcare Conference
Mar 5, 2013
BD at Raymond James Institutional Investors Conference
Mar 4, 2013
BD at Cowen Health Care Conference
Feb 27, 2013
BD at RBC Capital Markets' Healthcare Conference -
Feb 26, 2013
BD at Citi Global Healthcare Conference -
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | 13.80% | 14.39% |
| Operating margin | 19.05% | 20.21% |
| EBITD margin | - | 25.56% |
| Return on average assets | 9.52% | 10.18% |
| Return on average equity | 24.45% | 24.76% |
| Employees | 29,600 | - |
| Carbon Disclosure Rating | - | 59/100 |
Address
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. BD's operations consist of three business segments: BD Medical, BD Diagnostics and BD Biosciences. On February 9, 2012, the Company acquired a 100% interest in KIESTRA Lab Automation BV. On August 24, 2012, the Company acquired a 100% interest in Sirigen Group Limited. On October 31, 2012, the Company sold its BD Biosciences -Discovery Labware unit. In December 2012, the Company acquired Safety Syringes, Inc. Effective March 12, 2013, the Company acquired Cato Software Solutions GmbH.
Officers and directors
| Vincent A. Forlenza | Chairman of the Board, President, Chief Executive Officer | |
| Suketu Upadhyay | Acting Chief Financial Officer, Senior Vice President, Principal Accounting Officer, Controller | |
| Alexandre Conroy | President, Europe, EMA and the Americas | |
| James Lim | President, Greater Asia | |
| William A. Kozy | Chief Operating Officer, Executive Vice President | |
| Gary M Cohen | Executive Vice President | |
| Jeffrey S Sherman | Senior Vice President, General Counsel | |
| Donna M. Boles | Senior Vice President - Human Resources | |
| William E. Rhodes | Senior Vice President - Corporate Strategy and Development | |
| Stephen Sichak Jr. | Senior Vice President - Integrated Supply Chain |
